Background: Health-related cannabis has been obtainable in the State of Minnesota considering that July 2015 by way of the Minnesota Health-related Cannabis Program (MMCP). Objectives: Our study aimed to delineate oncology providers’ views on health-related cannabis, recognize barriers to patient enrollment, and assess clinicians’ interest in a clinical trial of health-related cannabis in sufferers with stage IV cancer. Strategies: From June to August 2017, we distributed a 14-query survey to Minnesota oncology physicians, sophisticated practice nurses, and doctor assistants who care for adults and kids with cancer. Descriptive analyses for each and every query have been supplied for all survey respondents. Outcomes: Of the 529 eligible survey participants, 153 (29%) responded to our survey 68 respondents have been registered with the MMCP. Most identified themselves as a health-related oncologist or health-related oncology nurse practitioner/doctor assistant (n=125, 82%), and most practiced in a neighborhood setting (n=102, 67%). All round, 65% of respondents supported the use of health-related cannabis. Perceived expense and inadequate investigation have been the highest barriers to MMCP patient enrollment. The lowest barriers incorporated lack of wellness group assistance for permitting certification of sufferers and danger of social stigma. Of all respondents, 36% lacked self-assurance in discussing the dangers and advantages of health-related cannabis, and 85% wanted far more education. Conclusions: Although assistance for cannabis use in the cancer setting is expanding, considerable barriers stay. This study illustrates a clear have to have to give clinicians each information and education to guide their discussions about the advantages, dangers, and expense considerations of using health-related cannabis for cancer-associated symptoms.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 30426072 PMCID: PMC6225592 DOI: 10.1089/can.2018.0029
Zylla D1,two, Steele G1,two, Eklund J1,two, Mettner Jtwo, Arneson Tthree.